Lamazym

DRUG7 trials

Sponsors

Zymenex A/S, Chiesi Farmaceutici S.p.A.

Conditions

Alpha MannosidosisAlpha-Mannosidosis

Phase 1

Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

CompletedNCT01268358

Zymenex A/SAlpha Mannosidosis

Start: 2010-10-31End: 2011-01-31Updated: 2020-08-03

Phase 2

Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Zymenex A/SAlpha Mannosidosis

Start: 2011-01-31End: 2012-11-30Updated: 2012-09-26

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

CompletedNCT01681940

Zymenex A/SAlpha-Mannosidosis

Start: 2012-01-31End: 2013-09-30Updated: 2017-03-29

Phase 3

A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

CompletedNCT01681953

Zymenex A/SAlpha-Mannosidosis

Start: 2012-08-31End: 2014-05-31Updated: 2020-08-03

Lamazym Aftercare Study

CompletedNCT01908725

Chiesi Farmaceutici S.p.A.Alpha-Mannosidosis

Start: 2013-06-30End: 2022-09-30Updated: 2023-07-28

Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients

CompletedNCT01908712

Chiesi Farmaceutici S.p.A.Alpha-Mannosidosis

Start: 2013-08-31End: 2022-09-30Updated: 2023-07-28

Evaluation of Long-term Efficacy of Treatment With Lamazym

CompletedNCT02478840

Zymenex A/SAlpha-Mannosidosis

Start: 2015-02-28End: 2015-06-30Updated: 2020-11-20

Related Papers

Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis

Journal of Inherited Metabolic Disease2024-10-097 citations